期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 313, 期 -, 页码 89-91出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2017.10.009
关键词
Alemtuzumab; Multiple sclerosis; Treatment response; CD4+lymphocytes; Immune reconstitution
资金
- Sanofi-Genzyme [Bio2009001]
Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4 + T cells. Here, we report the atypical CD4 + T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4 + cell percentage was not or just mildly affected and was slightly below the lowest normal limit already before alemtuzumab. These cases anticipate further studies aimed to investigate whether the evaluation of the CD4 + cell percentage could represent a helpful tool to address the individual clinical response to alemtuzumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据